<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686305</url>
  </required_header>
  <id_info>
    <org_study_id>D967YC00001</org_study_id>
    <nct_id>NCT04686305</nct_id>
  </id_info>
  <brief_title>Phase Ib Study of the Safety of T-DXd and Durvalumab With Chemotherapy in Advanced or Metastatic HER2+ Non-squamous NSCLC</brief_title>
  <acronym>DL03</acronym>
  <official_title>A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination With Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in&#xD;
      combination with durvalumab and chemotherapy in patients with HER2 positive advanced and&#xD;
      metastatic non-small cell lung cancer. The efficacy will be also analyzed as a secondary&#xD;
      endpoint.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 is a dose escalation study by design, allowing the assessment of safety, tolerability&#xD;
      and recommended dose levels of the combination of T-DXd and durvalumab plus cisplatin,&#xD;
      carboplatin or pemetrexed. In part 2, expansions in the treatment naïve setting on any&#xD;
      recommended dose level may take place to study preliminary efficacy as well.&#xD;
&#xD;
      The target population of interest are patients with advanced or metastatic non-small cell&#xD;
      lung cancer measurable disease by RECIST criteria, HER2 overexpression, ECOG PS of 0 to 1,&#xD;
      patients who have received 1 or 2 prior therapies for recurrent or metastatic disease (Part&#xD;
      1) and patients who are treatment naïve for recurrent or metastatic disease (Part 2)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">February 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 12, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will consist of 2 parts:&#xD;
Dose-escalation part and monotherapy arm (Part 1; second-line and third-line patients): The dose of T-DXd and chemotherapeutic components on Arms 1A, 1B and 1C (cisplatin, carboplatin or pemetrexed) will be modified during the dose-escalation part in order to find the RP2D. Durvalumab dose will remain fixed on the dose escalation part of the study. Arm 1D is the T-DXd monotherapy arm.&#xD;
Dose-expansion part (Part 2; treatment naïve patients for metastatic disease): may be initiated following dose escalation at the discretion of the sponsor.&#xD;
In addition to safety and tolerability, the study will also assess preliminary efficacy based upon ORR, DoR, DCR, OS, PFS among treatment groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of AEs and SAEs</measure>
    <time_frame>Safety will be assessed for approximately 20 months from informed consent</time_frame>
    <description>Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed Objective Response Rate (ORR)</measure>
    <time_frame>An average of approximately 12 months</time_frame>
    <description>Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed, based on investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>An average of approximately 20 months</time_frame>
    <description>DOR is defined as the time from the date of first documented response until the date of documented progression or death, based on RECIST assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>An average of approximately 12 months</time_frame>
    <description>DCR is the percentage of patients who have a best overall response of complete response (CR) or partial response (PR) or stable disease (SD), based on RECIST assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>An average of approximately 20 months</time_frame>
    <description>PFS is the time from first dose of study treatment until the date of objective disease progression or death, based on RECIST assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>An average of approximately 20 months</time_frame>
    <description>OS is the time form the date of first dose of study treatment until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AEs and SAEs</measure>
    <time_frame>Safety will be assessed for approximately 20 months from informed consent</time_frame>
    <description>Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) assessed by the serum concentration of T-DXd, total anti-HER2 antibody, and MAAA-1181 in all arms</measure>
    <time_frame>An average of approximately 20 months</time_frame>
    <description>Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for T-DXd, total anti-HER2 antibody and MAAA-1181a</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) assessed by the serum concentration of durvalumab in study arms including T-DXd in combination with durvalumab</measure>
    <time_frame>An average of approximately 20 months</time_frame>
    <description>Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for durvalumab, including T-DXd in combination with durvalumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The immunogenicity of T-DXd and durvalumab assessed by the presence of ADAs for T-DXd and durvalumab</measure>
    <time_frame>An average of approximately 20 months</time_frame>
    <description>Individual participant data and descriptive statistics will be provided for data at each time point for each dose level for T-DXd and durvalumab.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Locally Advanced or Metastatic Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1A: T-DXd, Durvalumab and Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd, Durvalumab and Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1B: T-DXd, Durvalumab and Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd, Durvalumab and Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1C: T-DXd, Durvalumab and Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd, Durvalumab and Pemetrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1D: T-DXd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2A: T-DXd, Durvalumab and Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd, Durvalumab and Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2B: T-DXd, Durvalumab and Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd, Durvalumab and Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2C: T-DXd, Durvalumab and Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd, Durvalumab and Pemetrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2D: T-DXd, Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd, Durvalumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab deruxtecan</intervention_name>
    <description>T-DXd: administered as an IV infusion</description>
    <arm_group_label>Arm 1A: T-DXd, Durvalumab and Cisplatin</arm_group_label>
    <arm_group_label>Arm 1B: T-DXd, Durvalumab and Carboplatin</arm_group_label>
    <arm_group_label>Arm 1C: T-DXd, Durvalumab and Pemetrexed</arm_group_label>
    <arm_group_label>Arm 1D: T-DXd</arm_group_label>
    <arm_group_label>Arm 2A: T-DXd, Durvalumab and Cisplatin</arm_group_label>
    <arm_group_label>Arm 2B: T-DXd, Durvalumab and Carboplatin</arm_group_label>
    <arm_group_label>Arm 2C: T-DXd, Durvalumab and Pemetrexed</arm_group_label>
    <arm_group_label>Arm 2D: T-DXd, Durvalumab</arm_group_label>
    <other_name>DS-8201a, T-DXd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab: administered as an IV infusion</description>
    <arm_group_label>Arm 1A: T-DXd, Durvalumab and Cisplatin</arm_group_label>
    <arm_group_label>Arm 1B: T-DXd, Durvalumab and Carboplatin</arm_group_label>
    <arm_group_label>Arm 1C: T-DXd, Durvalumab and Pemetrexed</arm_group_label>
    <arm_group_label>Arm 2A: T-DXd, Durvalumab and Cisplatin</arm_group_label>
    <arm_group_label>Arm 2B: T-DXd, Durvalumab and Carboplatin</arm_group_label>
    <arm_group_label>Arm 2C: T-DXd, Durvalumab and Pemetrexed</arm_group_label>
    <arm_group_label>Arm 2D: T-DXd, Durvalumab</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin: administered as an IV infusion</description>
    <arm_group_label>Arm 1A: T-DXd, Durvalumab and Cisplatin</arm_group_label>
    <arm_group_label>Arm 2A: T-DXd, Durvalumab and Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin: administered as an IV infusion</description>
    <arm_group_label>Arm 1B: T-DXd, Durvalumab and Carboplatin</arm_group_label>
    <arm_group_label>Arm 2B: T-DXd, Durvalumab and Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed: administered as an IV infusion</description>
    <arm_group_label>Arm 1C: T-DXd, Durvalumab and Pemetrexed</arm_group_label>
    <arm_group_label>Arm 2C: T-DXd, Durvalumab and Pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically documented unresectable locally advanced/metastatic non-squamous NSCLC&#xD;
&#xD;
          -  Part 1: Progression after 1 or 2 lines of systemic therapy for recurrent or metastatic&#xD;
             setting.&#xD;
&#xD;
          -  Part 2: Treatment-naïve for non curative treatment for locally advanced or metastatic&#xD;
             NSCLC.&#xD;
&#xD;
          -  Part 2: Patients must have tumors that lack activating EGFR mutations, EML4-ALK fusion&#xD;
             or other targetable alterations. Prior adjuvant, neoadjuvant therapies are permitted&#xD;
             if progression has occurred &gt; 12 months from the end of last therapy&#xD;
&#xD;
          -  HER2+ (IHC 3+ or IHC 2+) status as determined by central review of tumor tissue&#xD;
&#xD;
          -  WHO / ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Measurable target disease assessed by the investigator using RECIST 1.1&#xD;
&#xD;
          -  Has protocol defined adequate organ and bone marrow function&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  HER2 mutation if previously known&#xD;
&#xD;
          -  Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current&#xD;
             ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at&#xD;
             screening&#xD;
&#xD;
          -  Lung-specific intercurrent clinically significant illnesses including, but not limited&#xD;
             to, any underlying pulmonary disorder and prior pneumonectomy&#xD;
&#xD;
          -  Active primary immunodeficiency known HIV infection, or active hepatitis B or C&#xD;
             infection&#xD;
&#xD;
          -  Active infection including tuberculosis and uncontrolled infection requiring IV&#xD;
             antibiotics, antivirals, or antifungals&#xD;
&#xD;
          -  Spinal cord compression or clinically active central nervous system metastases,&#xD;
             defined as untreated and symptomatic, or requiring therapy with corticosteroids or&#xD;
             anticonvulsants to control associated symptoms&#xD;
&#xD;
          -  Medical history of myocardial infarction within 6 months before treatment assignment,&#xD;
             symptomatic CHF (New York Heart Association Class II to IV), clinically important&#xD;
             cardiac arrhythmias, or a recent (&lt; 6 months) cardiovascular event including stroke&#xD;
&#xD;
          -  A pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal&#xD;
             shunt, or CART (Concentrated Ascites Reinfusion Therapy)&#xD;
&#xD;
          -  Unresolved toxicities from previous anticancer therapy OR prior discontinuation of any&#xD;
             planned study therapy due to toxicity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>George Town</city>
        <zip>10450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Selangor</city>
        <zip>62250</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bacolod</city>
        <zip>6100</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Davao City</city>
        <zip>PH-8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manila</city>
        <zip>1015</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1112</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Juan</city>
        <zip>1500</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taguig City</city>
        <zip>1634</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badalona</city>
        <zip>08013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung city</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung City</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10300</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hat Yai</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muang</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2+</keyword>
  <keyword>DS-8201a</keyword>
  <keyword>T-DXd</keyword>
  <keyword>Trastuzumab Deruxtecan</keyword>
  <keyword>Locally advanced and unresectable non-squamous NSCLC</keyword>
  <keyword>Metastatic non-squamous NSCLC</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

